Christopher M OConnor
Overview
Explore the profile of Christopher M OConnor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
735
Citations
24024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canepa M, Anastasia G, Ameri P, Vergallo R, OConnor C, Sinagra G, et al.
Eur J Intern Med
. 2025 Feb;
PMID: 39939263
Aims: We investigated how ischemic etiology has been assigned in heart failure with a reduced ejection fraction (HFrEF) randomized controlled trials (RCTs). Methods And Results: We performed a systematic review...
2.
Lavie C, Tutor A, Mehra M, OConnor C
Mayo Clin Proc
. 2024 Dec;
99(12):1857-1859.
PMID: 39631982
No abstract available.
3.
OConnor C, Rosner C, Gill A, Speir A, Neville R
Front Cardiovasc Med
. 2024 Nov;
11:1409303.
PMID: 39512365
Inova Schar Heart and Vascular has an unwavering commitment to delivering excellent cardiovascular care and has integrated principles of a learning health care system to develop our system of continuous...
4.
Cunningham J, Abraham W, Bhatt A, Dunn J, Felker G, Jain S, et al.
J Am Coll Cardiol
. 2024 Nov;
84(20):2051-2062.
PMID: 39505413
Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI)...
5.
Kittipibul V, Mentz R, Young R, Butler J, Ezekowitz J, Lam C, et al.
ESC Heart Fail
. 2024 Oct;
PMID: 39434631
Aims: The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This...
6.
Dimond M, Rosner C, Lee S, Shakoor U, Samadani T, Batchelor W, et al.
ESC Heart Fail
. 2024 Sep;
12(1):60-70.
PMID: 39327768
Aims: Despite significant morbidity and mortality, recent advances in cardiogenic shock (CS) management have been associated with increased survival. However, little is known regarding the management of patients who survive...
7.
deFilippi C, Shah P, Shah S, Alemayehu W, Lam C, Butler J, et al.
Circ Heart Fail
. 2024 Aug;
17(9):e011792.
PMID: 39206547
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that may emerge from overlapping systemic processes associated with comorbidities. We assessed whether unique clusters of circulating proteins...
8.
Westerhout C, Rathwell S, Anstrom K, Hernandez A, Ponikowski P, Ezekowitz J, et al.
J Card Fail
. 2024 Aug;
31(3):551-558.
PMID: 39182825
Background: In VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), participants with heart failure (HF) and reduced ejection fraction, vericiguat decreased the primary composite outcome...
9.
Rao V, Hellkamp A, Thomas L, Fonarow G, Fiuzat M, OConnor C, et al.
JACC Heart Fail
. 2024 Aug;
12(11):1862-1875.
PMID: 39115518
Background: Optimal medical therapy (OMT) scoring may stratify clinical risk in real-world chronic heart failure with reduced ejection fraction (HFrEF) by integrating use and dosing of guideline-directed medical therapy (GDMT)...
10.
Tromp J, Lam C, Alemayehu W, de Filippi C, Melenovsky V, Sliwa K, et al.
Eur J Heart Fail
. 2024 Jul;
26(10):2231-2239.
PMID: 39078607
Aims: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated...